Intravenous zoledronic acid in postmenopausal women with low bone mineral density

Ian R. Reid, Jacques P. Brown, Peter Burckhardt, Zebulun Horowitz, Peter Richardson, Ulrich Trechsel, Albert Widmer, Jean Pierre Devogelaer, Jean Marc Kaufman, Philippe Jaeger, Jean Jacques Body, Maria Luisa Brandi, Johann Broell, Raffaele Di Micco, Andrea Riccardo Genazzani, Dieter Felsenberg, Joachim Happ, Michael J. Hooper, Jochen Ittner, Georg Leb & 8 others Hans Mallmin, Timothy Murray, Sergio Ortolani, Alessandro Rubinacci, Maria Sääf, Goran Samsioe, Leon Verbruggen, Pierre J. Meunier

Research output: Contribution to journalArticle

682 Citations (Scopus)

Abstract

Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P

Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalNew England Journal of Medicine
Volume346
Issue number9
DOIs
Publication statusPublished - Feb 28 2002

Fingerprint

zoledronic acid
Bone Density
Placebos
Diphosphonates
Spine
Bone Remodeling
Biological Availability
Osteoporosis
Compliance
Stomach

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., ... Meunier, P. J. (2002). Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine, 346(9), 653-661. https://doi.org/10.1056/NEJMoa011807

Intravenous zoledronic acid in postmenopausal women with low bone mineral density. / Reid, Ian R.; Brown, Jacques P.; Burckhardt, Peter; Horowitz, Zebulun; Richardson, Peter; Trechsel, Ulrich; Widmer, Albert; Devogelaer, Jean Pierre; Kaufman, Jean Marc; Jaeger, Philippe; Body, Jean Jacques; Brandi, Maria Luisa; Broell, Johann; Micco, Raffaele Di; Genazzani, Andrea Riccardo; Felsenberg, Dieter; Happ, Joachim; Hooper, Michael J.; Ittner, Jochen; Leb, Georg; Mallmin, Hans; Murray, Timothy; Ortolani, Sergio; Rubinacci, Alessandro; Sääf, Maria; Samsioe, Goran; Verbruggen, Leon; Meunier, Pierre J.

In: New England Journal of Medicine, Vol. 346, No. 9, 28.02.2002, p. 653-661.

Research output: Contribution to journalArticle

Reid, IR, Brown, JP, Burckhardt, P, Horowitz, Z, Richardson, P, Trechsel, U, Widmer, A, Devogelaer, JP, Kaufman, JM, Jaeger, P, Body, JJ, Brandi, ML, Broell, J, Micco, RD, Genazzani, AR, Felsenberg, D, Happ, J, Hooper, MJ, Ittner, J, Leb, G, Mallmin, H, Murray, T, Ortolani, S, Rubinacci, A, Sääf, M, Samsioe, G, Verbruggen, L & Meunier, PJ 2002, 'Intravenous zoledronic acid in postmenopausal women with low bone mineral density', New England Journal of Medicine, vol. 346, no. 9, pp. 653-661. https://doi.org/10.1056/NEJMoa011807
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine. 2002 Feb 28;346(9):653-661. https://doi.org/10.1056/NEJMoa011807
Reid, Ian R. ; Brown, Jacques P. ; Burckhardt, Peter ; Horowitz, Zebulun ; Richardson, Peter ; Trechsel, Ulrich ; Widmer, Albert ; Devogelaer, Jean Pierre ; Kaufman, Jean Marc ; Jaeger, Philippe ; Body, Jean Jacques ; Brandi, Maria Luisa ; Broell, Johann ; Micco, Raffaele Di ; Genazzani, Andrea Riccardo ; Felsenberg, Dieter ; Happ, Joachim ; Hooper, Michael J. ; Ittner, Jochen ; Leb, Georg ; Mallmin, Hans ; Murray, Timothy ; Ortolani, Sergio ; Rubinacci, Alessandro ; Sääf, Maria ; Samsioe, Goran ; Verbruggen, Leon ; Meunier, Pierre J. / Intravenous zoledronic acid in postmenopausal women with low bone mineral density. In: New England Journal of Medicine. 2002 ; Vol. 346, No. 9. pp. 653-661.
@article{57f67b935635440c9f28eba897bc2050,
title = "Intravenous zoledronic acid in postmenopausal women with low bone mineral density",
abstract = "Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P",
author = "Reid, {Ian R.} and Brown, {Jacques P.} and Peter Burckhardt and Zebulun Horowitz and Peter Richardson and Ulrich Trechsel and Albert Widmer and Devogelaer, {Jean Pierre} and Kaufman, {Jean Marc} and Philippe Jaeger and Body, {Jean Jacques} and Brandi, {Maria Luisa} and Johann Broell and Micco, {Raffaele Di} and Genazzani, {Andrea Riccardo} and Dieter Felsenberg and Joachim Happ and Hooper, {Michael J.} and Jochen Ittner and Georg Leb and Hans Mallmin and Timothy Murray and Sergio Ortolani and Alessandro Rubinacci and Maria S{\"a}{\"a}f and Goran Samsioe and Leon Verbruggen and Meunier, {Pierre J.}",
year = "2002",
month = "2",
day = "28",
doi = "10.1056/NEJMoa011807",
language = "English",
volume = "346",
pages = "653--661",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - Intravenous zoledronic acid in postmenopausal women with low bone mineral density

AU - Reid, Ian R.

AU - Brown, Jacques P.

AU - Burckhardt, Peter

AU - Horowitz, Zebulun

AU - Richardson, Peter

AU - Trechsel, Ulrich

AU - Widmer, Albert

AU - Devogelaer, Jean Pierre

AU - Kaufman, Jean Marc

AU - Jaeger, Philippe

AU - Body, Jean Jacques

AU - Brandi, Maria Luisa

AU - Broell, Johann

AU - Micco, Raffaele Di

AU - Genazzani, Andrea Riccardo

AU - Felsenberg, Dieter

AU - Happ, Joachim

AU - Hooper, Michael J.

AU - Ittner, Jochen

AU - Leb, Georg

AU - Mallmin, Hans

AU - Murray, Timothy

AU - Ortolani, Sergio

AU - Rubinacci, Alessandro

AU - Sääf, Maria

AU - Samsioe, Goran

AU - Verbruggen, Leon

AU - Meunier, Pierre J.

PY - 2002/2/28

Y1 - 2002/2/28

N2 - Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P

AB - Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P

UR - http://www.scopus.com/inward/record.url?scp=0037186926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037186926&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa011807

DO - 10.1056/NEJMoa011807

M3 - Article

VL - 346

SP - 653

EP - 661

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -